American Heart Journal
Volume 145, Issue 5 , Pages 754-757 , May 2003

What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

  • Kenneth Dickstein

      Affiliations

    • University of Bergen, Central Hospital in Rogaland, Stavanger, Norway
    • Corresponding Author InformationReprint requests: Kenneth Dickstein,University of Bergen, Central Hospital in Rogaland, Stavanger, Norway.

References 

  1. Dickstein K, Kjekshus J  OPTIMAAL Trial Steering Committee . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction (the OPTIMAAL randomised trial). Lancet. 2002;360:752–760
  2. Pfeffer M, McMurray J, Leizorovicz A, et al.  Valsartan in acute myocardial infarction trial (VALIANT) (rationale and design). Am Heart J. 2000;140:727–734
  3. Pfeffer M. ACE inhibitors in acute myocardial infarction (patient selection and timing). Circulation. 1998;97:2192–2194
  4. Dickstein K, Kjekshus J  OPTIMAAL Trial Steering Committee . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction (the OPTIMAAL randomised trial). Lancet. 2002;360:752–760
  5. Pitt B, Poole-Wilson P, Segal R, et al.  Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure (the losartan heart failure survival study–ELITE II). Lancet. 2000;355:1582–1587
  6. Tang W, Vagelos R, Yee Y, et al.  Neurohumoral and clinical responses to high vs low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39:70–78
  7. Gottleib S, Dickstein K, Fleck E, et al.  Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602–1609
  8. Latini R, Maggioni AP, Flather M, et al.  ACE inhibitor use in patients with myocardial infarction (summary of evidence from clinical trials). Circulation. 1995;92:3132–3137
  9. Brenner B, Cooper M, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861–869
  10. Dahlöf B, Devereux RB, Kjeldsen S, et al.  Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol). Lancet. 2002;359:995–1003
  11. ACE Inhibitor Myocardial Infarction Collaborative Group . Indications for ACE inhibitors in the early treatment of acute myocardial infarction (systematic overview of individual data from 100 000 patients in randomised trials). Circulation. 1998;97:2202–2212
  12. Cohn JN, Tognoni G  Val-HeFT Investigators . Effect of the angiotensin blocker valsartan on morbidity and mortality in heart failure (the valsartan heart failure trial (Val-HeFT)). N Engl J Med. 2001;345:1667–1675
  13. Maggioni A, Anand I, Gottlieb S, et al.  Effets of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414–1421
  14. Valsartan approved for heart failure patients intolerant of ACE inhibitors. HeartWire News. Available at: http: www.theheart.org. Last accessed August 15, 2002
  15. Swedberg K, Pfeffer M, Granger G, et al.  Candesartan in heart failure–assessment of reduction in mortality (CHARM) (rationale and design). J Card Failure. 1999;5:276–282
  16. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:812–828
  17. Pfeffer MA, Braunwald E, Moyé LA, et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–677
  18. Køber I, Torp-Pedersen C, Carlson JE, et al.  A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;353:1670–1676
  19. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80–85
  20. Abbas A, Rybicki B, Alam M, et al.  Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999;138:1133–1139
  21. ISIS-4 Collaborative Group . ISIS-4 (a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulfate in over 58,050 patients with suspected acute myocardial infarction). Lancet. 1995;345:669–685
  22. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico . GISSI-3 (effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction). Lancet. 1994;343:1115–1122
  23. Hall S, Sapsford R, Megary S, et al.  Inhibition of the renin-angiotensin system after acute myocardial infarction (treat first, select later?). Heart. 1996;76:73–78

PII: S0002-8703(03)00168-6

doi: 10.1016/S0002-8703(03)00168-6

American Heart Journal
Volume 145, Issue 5 , Pages 754-757 , May 2003

Article Tools